Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic

Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID-19). However, apart from remdesivir, there is a paucity of other specific anti-viral agents against SARS-CoV-2 infection. In 2017...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallianou, Natalia G., Tsilingiris, Dimitrios, Christodoulatos, Gerasimos Socrates, Karampela, Ιrene, Dalamaga, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles from the Vaccines, Immune Response, Therapeutic interventions and COVID-19 Special Issue
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143911/
https://www.ncbi.nlm.nih.gov/pubmed/34056571
http://dx.doi.org/10.1016/j.metop.2021.100096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143911/
https://www.ncbi.nlm.nih.gov/pubmed/34056571
http://dx.doi.org/10.1016/j.metop.2021.100096

Ejemplares similares